title: Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa.
abstract: To know the effects of sex steroids on the potentials of growth, invasion, and metastasis with neovascularization of endometrial cancer, the expression of plasminogen activator inhibitor (PAI)-1 [an inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA)] and its mRNA in well-differentiated uterine endometrial cancer cell line Ishikawa was determined by an enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction-Southern blotting (RT-PCR-SB), respectively, under the influence of sex steroids. In Ishikawa cells, either estradiol or progestins (progesterone, medroxyprogesterone acetate, or 17 alpha-hydroxyprogesterone alone) induced the expression of PAI-1 and its mRNA, and those expressions were increased approximately two-fold by both estradiol and progestin administered together. Therefore, sex steroidal induction of PAI-1 might contribute to the inhibition of invasion and metastasis, concomitantly with the inhibition of neovascularization associated with tPA and uPA activities, in well differentiated endometrial cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Gifu University School of Medicine, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Fujimoto
authors.forename: M
authors.initials: M
authors.lastname: Hori
authors.forename: S
authors.initials: S
authors.lastname: Ichigo
authors.forename: T
authors.initials: T
authors.lastname: Tamaya
mesh_terms: D019326:17-alpha-Hydroxyprogesterone / Q000494:pharmacology; D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology*; D004273:DNA, Neoplasm / Q000235:genetics; D016889:Endometrial Neoplasms / Q000235:genetics / Q000473:pathology*; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D012739:Gonadal Steroid Hormones / Q000494:pharmacology*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009389:Neovascularization, Pathologic / Q000503:physiopathology; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis* / Q000235:genetics; D016133:Polymerase Chain Reaction; D011374:Progesterone / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis*; D012334:RNA, Neoplasm / Q000096:biosynthesis*; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000096:biosynthesis / Q000235:genetics
chemical_list: D004273:DNA, Neoplasm; D012739:Gonadal Steroid Hormones; D009363:Neoplasm Proteins; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011374:Progesterone; D004958:Estradiol; D019326:17-alpha-Hydroxyprogesterone; D017258:Medroxyprogesterone Acetate; D014568:Urokinase-Type Plasminogen Activator